Literature DB >> 17255262

Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma.

Satoru Seo1, Etsuro Hatano, Tatsuya Higashi, Tadashi Hara, Masaharu Tada, Nobuyuki Tamaki, Keiko Iwaisako, Iwao Ikai, Shinji Uemoto.   

Abstract

PURPOSE: To investigate the diagnostic value of fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) for prediction of tumor differentiation, P-glycoprotein (P-gp) expression, and outcome in hepatocellular carcinoma (HCC) patients. EXPERIMENTAL
DESIGN: Seventy HCC patients who underwent curative resection were prospectively enrolled in the study. FDG-PET was done 2 weeks preoperatively, and the standardized uptake value (SUV) and the tumor to nontumor SUV ratio (TNR) were calculated from FDG uptake. Tumor differentiation and P-gp expression were examined with H&E and immunohistochemical staining, respectively.
RESULTS: SUV and TNR were significantly higher in poorly differentiated HCCs than in well-differentiated (P = 0.001 and 0.002) and moderately differentiated HCCs (P < 0.0001 and P < 0.0001). The percentage P-gp-positive area was significantly higher in well-differentiated HCCs than in poorly differentiated (P < 0.0001) and moderately differentiated HCCs (P = 0.0001). Inverse correlations were found between SUV and P-gp expression (r = -0.44; P < 0.0001) and between TNR and P-gp expression (r = -0.47; P = 0.01). Forty-three (61.4%) patients had postoperative recurrence. The overall and disease-free survival rates in the high TNR (> or =2.0) group were significantly lower than in the low TNR (<2.0) group (P = 0.0001 and 0.0002). In multivariate analysis, a high alpha-fetoprotein level (risk ratio, 5.46; P = 0.003; risk ratio, 8.78; P = 0.006) and high TNR (risk ratio, 1.3; P = 0.03; risk ratio, 1.6; P = 0.02) were independent predictors of postoperative recurrence and overall survival.
CONCLUSIONS: The results suggest that preoperative FDG-PET reflects tumor differentiation and P-gp expression and may be a good predictor of outcome in HCC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17255262     DOI: 10.1158/1078-0432.CCR-06-1357

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  63 in total

1.  Liver-specific contrast agent-enhanced magnetic resonance and ¹⁸F-fluorodeoxyglucose positron emission tomography findings of hepatocellular adenoma: report of a case.

Authors:  Tatsuaki Sumiyoshi; Michihisa Moriguchi; Hideyuki Kanemoto; Kouiku Asakura; Keiko Sasaki; Teiichi Sugiura; Takashi Mizuno; Katsuhiko Uesaka
Journal:  Surg Today       Date:  2011-12-10       Impact factor: 2.549

2.  Clinical utility and limitations of FDG PET in detecting recurrent hepatocellular carcinoma in postoperative patients.

Authors:  Nobuyuki Hayakawa; Yuji Nakamoto; Koya Nakatani; Etsuro Hatano; Satoru Seo; Tatsuya Higashi; Tsuneo Saga; Shinji Uemoto; Kaori Togashi
Journal:  Int J Clin Oncol       Date:  2013-12-25       Impact factor: 3.402

Review 3.  Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we?

Authors:  Yu-Yun Shao; Chih-Hung Hsu; Ann-Lii Cheng
Journal:  Liver Cancer       Date:  2013-04       Impact factor: 11.740

Review 4.  Positron emission tomography diagnostic imaging in multidrug-resistant hepatocellular carcinoma: focus on 2-deoxy-2-(18F)Fluoro-D-Glucose.

Authors:  Ana F Brito; Mónica Mendes; Ana M Abrantes; José G Tralhão; Maria F Botelho
Journal:  Mol Diagn Ther       Date:  2014-10       Impact factor: 4.074

5.  Unexpected FDG-PET uptake in the gastrointestinal tract: endoscopic and histopathological correlations.

Authors:  Eran Goldin; Mahmud Mahamid; Benjamin Koslowsky; Shimon Shteingart; Yael Dubner; Gadi Lalazar; Dov Wengrower
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

6.  18F-fluorodeoxyglucose PET/CT predicts tumour progression after transarterial chemoembolization in hepatocellular carcinoma.

Authors:  Myeong Jun Song; Si Hyun Bae; Sung Won Lee; Do Sun Song; Hee Yeon Kim; Ie Ryung Yoo; Joon-Il Choi; Young June Lee; Ho Jong Chun; Hae Giu Lee; Jong Young Choi; Seung Kew Yoon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-22       Impact factor: 9.236

Review 7.  Functional imaging of hepatocellular carcinoma.

Authors:  Tim Ch Hoogenboom; Mark Thursz; Eric O Aboagye; Rohini Sharma
Journal:  Hepat Oncol       Date:  2016-03-29

8.  Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment.

Authors:  Daiki Yamashige; Yusuke Kawamura; Masahiro Kobayashi; Junichi Shindoh; Yuta Kobayashi; Satoshi Okubo; Nozomu Muraishi; Akira Kajiwara; Soichi Iritani; Shunichiro Fujiyama; Tetsuya Hosaka; Satoshi Saitoh; Hitomi Sezaki; Norio Akuta; Fumitaka Suzuki; Yoshiyuki Suzuki; Kenji Ikeda; Yasuji Arase; Masaji Hashimoto; Hiromitsu Kumada
Journal:  Oncology       Date:  2020-11-18       Impact factor: 2.935

9.  FDG PET as a prognostic predictor in the early post-therapeutic evaluation for unresectable hepatocellular carcinoma.

Authors:  Tatsuya Higashi; Etsuro Hatano; Iwao Ikai; Ryuichi Nishii; Yuji Nakamoto; Koichi Ishizu; Tsuyoshi Suga; Hidekazu Kawashima; Kaori Togashi; Satoru Seo; Koji Kitamura; Yasutsugu Takada; Yasuji Takada; Shinji Uemoto; Shinji Kamimoto
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10-17       Impact factor: 9.236

10.  Complete Metabolic Response with Recanalization of Portal Vein Tumor Thrombosis after Sunitinib in a Patient with Advanced Hepatocellular Carcinoma.

Authors:  Michele Basso; Maria Basso; Alessandro Iaculli; Maurizio Pompili; Laura Riccardi; Brunella Barbaro; Vittoria Rufini; Alessandra Cassano; Paola Castaldi; Carlo Barone
Journal:  Case Rep Oncol       Date:  2010-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.